WO2003104803A3 - METHOD OF CARTOGRAPHY AND ELIMINATION OF T EPITOPES - Google Patents

METHOD OF CARTOGRAPHY AND ELIMINATION OF T EPITOPES Download PDF

Info

Publication number
WO2003104803A3
WO2003104803A3 PCT/EP2003/006110 EP0306110W WO03104803A3 WO 2003104803 A3 WO2003104803 A3 WO 2003104803A3 EP 0306110 W EP0306110 W EP 0306110W WO 03104803 A3 WO03104803 A3 WO 03104803A3
Authority
WO
WIPO (PCT)
Prior art keywords
epitopes
identification
relates
ligands
mapping
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2003/006110
Other languages
French (fr)
Other versions
WO2003104803A2 (en
Inventor
Matthew Baker
Francis J Carr
Graham Carter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29724386&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2003104803(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to MXPA04012209A priority Critical patent/MXPA04012209A/en
Priority to BR0311720-0A priority patent/BR0311720A/en
Priority to AU2003273679A priority patent/AU2003273679A1/en
Priority to EP03740219A priority patent/EP1512004B1/en
Priority to CA002489180A priority patent/CA2489180A1/en
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Priority to DE60304040T priority patent/DE60304040T2/en
Priority to JP2004511824A priority patent/JP2005529170A/en
Publication of WO2003104803A2 publication Critical patent/WO2003104803A2/en
Publication of WO2003104803A3 publication Critical patent/WO2003104803A3/en
Priority to US11/009,460 priority patent/US20050181459A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in epitope analysis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Diaphragms For Electromechanical Transducers (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne des méthodes de criblage destinées à l'identification de déterminants et d'épitopes sur des molécules protéiques capables d'induire une réponse immune. L'invention concerne plus particulièrement l'identification d'épitopes T dans des protéines thérapeutiques. Finalement, l'invention concerne une approche combinée faisant intervenir la cartographie des épitopes et l'identification de ligands de molécules du CMH de classe II dérivant de ladite méthode de cartographie des épitopes, ainsi que la conception de séquences analogues ayant un nombre réduit de ces ligands et épitopes, respectivement.The invention relates to screening methods for the identification of determinants and epitopes on protein molecules capable of inducing an immune response. The invention relates more particularly to the identification of T epitopes in therapeutic proteins. Finally, the invention relates to a combined approach involving the mapping of epitopes and the identification of ligands for MHC class II molecules derived from said method of mapping epitopes, as well as the design of analogous sequences having a reduced number of these ligands and epitopes, respectively.

PCT/EP2003/006110 2002-06-11 2003-06-11 Method for mapping and eliminating t-cell epitopes Ceased WO2003104803A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
JP2004511824A JP2005529170A (en) 2002-06-11 2003-06-11 Methods for mapping and removing T cell epitopes
BR0311720-0A BR0311720A (en) 2002-06-11 2003-06-11 Method for mapping and eliminating t-cell epitopes
AU2003273679A AU2003273679A1 (en) 2002-06-11 2003-06-11 Method for mapping and eliminating t-cell epitopes
EP03740219A EP1512004B1 (en) 2002-06-11 2003-06-11 Method for mapping and eliminating t-cell epitopes
CA002489180A CA2489180A1 (en) 2002-06-11 2003-06-11 Method for mapping and eliminating t-cell epitopes
MXPA04012209A MXPA04012209A (en) 2002-06-11 2003-06-11 Method for mapping and eliminating t-cell epitopes.
DE60304040T DE60304040T2 (en) 2002-06-11 2003-06-11 METHOD FOR IDENTIFYING AND ELIMINATING T-CELL EPITOPES
US11/009,460 US20050181459A1 (en) 2002-06-11 2004-12-10 Method for mapping and eliminating T cell epitopes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02012919.3 2002-06-11
EP02012919 2002-06-11

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/009,460 Continuation-In-Part US20050181459A1 (en) 2002-06-11 2004-12-10 Method for mapping and eliminating T cell epitopes

Publications (2)

Publication Number Publication Date
WO2003104803A2 WO2003104803A2 (en) 2003-12-18
WO2003104803A3 true WO2003104803A3 (en) 2004-04-15

Family

ID=29724386

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/006110 Ceased WO2003104803A2 (en) 2002-06-11 2003-06-11 Method for mapping and eliminating t-cell epitopes

Country Status (16)

Country Link
EP (1) EP1512004B1 (en)
JP (1) JP2005529170A (en)
CN (1) CN100401064C (en)
AT (1) ATE320603T1 (en)
AU (1) AU2003273679A1 (en)
BR (1) BR0311720A (en)
CA (1) CA2489180A1 (en)
DE (1) DE60304040T2 (en)
DK (1) DK1512004T3 (en)
ES (1) ES2257680T3 (en)
MX (1) MXPA04012209A (en)
PL (1) PL371675A1 (en)
PT (1) PT1512004E (en)
RU (1) RU2334235C2 (en)
WO (1) WO2003104803A2 (en)
ZA (1) ZA200500214B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004213565A1 (en) * 2003-02-18 2004-09-02 Merck Patent Gmbh Fusion proteins of interferon alpha muteins with improved properties
CA2560278C (en) 2004-03-19 2012-11-20 Matthew Baker Modified bouganin proteins, cytotoxins and methods and uses thereof
FR2940451B1 (en) 2008-12-18 2014-09-12 Proteus METHOD FOR EVALUATING IMMUNOGENICITY OF PROTEINS
GB201917630D0 (en) * 2019-12-03 2020-01-15 Ge Healthcare Bio Sciences Ab Method for determination of aggregates

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2349463A (en) * 1996-03-21 2000-11-01 Circassia Ltd Method for identification of cryptic peptides
WO2002040997A2 (en) * 2000-10-02 2002-05-23 Genencor International, Inc. Production and use of proteins producing an altered immunogenic response

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001349A (en) * 1995-02-22 1999-12-14 Therion Biologics Corporation Generation of human cytotoxic T-cells specific for carcinoma self-associated antigens and uses thereof
US5945401A (en) * 1995-06-23 1999-08-31 Conlon; Paul J. Peptide analogues of the 65KD isoform of human glutamic acid decarboxylase and uses thereof
US6165460A (en) * 1995-07-10 2000-12-26 Therion Biologics Corporation Generation of immune responses to prostate-specific antigen (PSA)
US5750356A (en) * 1996-05-31 1998-05-12 Anergen, Inc. Method for monitoring T cell reactivity
EP0983303B1 (en) * 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
AU776910B2 (en) * 1998-12-08 2004-09-23 Merck Patent Gesellschaft Mit Beschrankter Haftung Modifying protein immunogenicity

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2349463A (en) * 1996-03-21 2000-11-01 Circassia Ltd Method for identification of cryptic peptides
WO2002040997A2 (en) * 2000-10-02 2002-05-23 Genencor International, Inc. Production and use of proteins producing an altered immunogenic response

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
HIEMSTRA HOEBERT S ET AL: "The identification of CD4+ T cell epitopes with dedicated synthetic peptide libraries", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 94, no. 19, 1997, 1997, pages 10313 - 10318, XP002269742, ISSN: 0027-8424 *
LAUNOIS PASCAL ET AL: "T-cell-epitope mapping of the major secreted mycobacterial antigen Ag85A in tuberculosis and leprosy", INFECTION AND IMMUNITY, vol. 62, no. 9, 1994, pages 3679 - 3687, XP000572211, ISSN: 0019-9567 *
REECE JEANETTE C ET AL: "Mapping the major human T helper epitopes of tetanus toxin. The emerging picture", JOURNAL OF IMMUNOLOGY, vol. 151, no. 11, 1993, pages 6175 - 6184, XP002269741, ISSN: 0022-1767 *
WARMERDAM PETRA A M ET AL: "Staphylokinase-specific cell-mediated immunity in humans.", JOURNAL OF IMMUNOLOGY, vol. 168, no. 1, 1 January 2002 (2002-01-01), pages 155 - 161, XP002269743, ISSN: 0022-1767 (ISSN print) *

Also Published As

Publication number Publication date
DK1512004T3 (en) 2006-06-06
ATE320603T1 (en) 2006-04-15
RU2005100758A (en) 2006-01-20
WO2003104803A2 (en) 2003-12-18
PL371675A1 (en) 2005-06-27
BR0311720A (en) 2005-03-01
DE60304040D1 (en) 2006-05-11
JP2005529170A (en) 2005-09-29
ES2257680T3 (en) 2006-08-01
AU2003273679A1 (en) 2003-12-22
CN100401064C (en) 2008-07-09
RU2334235C2 (en) 2008-09-20
EP1512004B1 (en) 2006-03-15
CN1659437A (en) 2005-08-24
DE60304040T2 (en) 2006-09-28
ZA200500214B (en) 2006-02-22
EP1512004A2 (en) 2005-03-09
CA2489180A1 (en) 2003-12-18
PT1512004E (en) 2006-08-31
MXPA04012209A (en) 2005-02-25

Similar Documents

Publication Publication Date Title
Calvete et al. Venoms, venomics, antivenomics
Pisarewicz et al. Polypeptide chains containing d-γ-hydroxyvaline
Nirujogi et al. Moving from unsequenced to sequenced genome: reanalysis of the proteome of Leishmania donovani
BRPI0516356A (en) yeast therapy for chronic hepatitis c infections
NI200700021A (en) DIRECTED ANTIBODIES AGAINST BETA-AMYLOID PEPTIDE AND PROCEDURES USING THE SAME. PC19496A
BR122018016045B8 (en) optimized variant protein
ATE382364T1 (en) PEPTIDE DERIVED FROM IGF BINDING PROTEIN
EP1541686A4 (en) CONSTRUCTION OF ANTIBODY USING A MRL / LPR MOUSE
Davenport et al. Reverse immunogenetics: from HLA-disease associations to vaccine candidates
BRPI0407207A (en) Method to Treat, Prevent, and Diagnose a Heliocobacter Infection
NO20081043L (en) Vaccine for fish
Engelhard How cells process antigens
Mohien et al. A bioinformatics approach for integrated transcriptomic and proteomic comparative analyses of model and non-sequenced anopheline vectors of human malaria parasites
Parthasarathy et al. Defeating the trypanosomatid trio: proteomics of the protozoan parasites causing neglected tropical diseases
Masforrol et al. A deeper mining on the protein composition of VA-MENGOC-BC®: An OMV-based vaccine against N. meningitidis serogroup B and C
NO20070757L (en) New sequence for enhancing expression of nucleic acid (s)
ATE460670T1 (en) REAGENTS AND A METHOD FOR SATURATION LABELING OF PROTEINS
ATE316577T1 (en) THE GOODPASTURE ANTIGEN BINDING PROTEIN
BR0312282A (en) Process for the enrichment and detection of pathologically modified prion proteins (prpsc)
CY1105380T1 (en) PREFERRED NEURAL FILAMENT PROTEIN PORTIONS AND METHODS OF USING THEREOF
EP1140978A4 (en) METHODS OF IDENTIFYING GENE SEQUENCES OF ANTIGENS
WO2006066153A8 (en) Actinomadura chromoprotein, apoprotein, and gene cluster
BRPI0416201A (en) methods for purification of pertussis toxin and its usable peptides
Gastaldello et al. The immunopeptidomes of two transmissible cancers and their host have a common, dominant peptide motif
DE60330780D1 (en) SEQUENCES OF T-CELL RECEPTOR CDR3 AND DETECTION METHOD

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2003740219

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: PA/a/2004/012209

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2489180

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 20038134519

Country of ref document: CN

Ref document number: 1020047020181

Country of ref document: KR

Ref document number: 11009460

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2004511824

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2005/00214

Country of ref document: ZA

Ref document number: 200500214

Country of ref document: ZA

ENP Entry into the national phase

Ref document number: 2005100758

Country of ref document: RU

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2003273679

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 1020047020181

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2003740219

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 2003740219

Country of ref document: EP